Louis Garguilo
ARTICLES BY LOUIS
-
Things have progressed nicely for Ruby Casareno, Vice President, Chemistry, Manufacturing and Controls (CMC), Allakos Inc. For executives wishing the same for your CMC leadership and organization, there are lessons on why that’s the case. Those lessons also recall for Casareno an earlier experience where progression traversed a rockier road. It all adds up to 6 best practices particular to outsourcing drug development and manufacturing.
-
Jim Bonner of Shire, Eric Jayjock of Patheon, and Doug Hausner, of Rutgers University, all agree continuous manufacturing is the pharmaceutical industry’s future. They also agree on the map and vehicle to get us past some of the roadblocks to that destination.
-
The journey to implementation of the disruptive technology of continuous manufacturing began in 2005, according to Markus Krumme of Novartis, with a single question on a slide presented to Novartis development and manufacturing executives. “Why don’t we have facilities that can continuously produce materials?” then-CEO Daniel Vasella asked.